• Non ci sono risultati.

Syncope in Patients with Autonomic Nervous System Disturbances: Which Diagnosis and Treatment?

N/A
N/A
Protected

Academic year: 2022

Condividi "Syncope in Patients with Autonomic Nervous System Disturbances: Which Diagnosis and Treatment?"

Copied!
11
0
0

Testo completo

(1)

Disturbances: Which Diagnosis and Treatment?

C.J. M

ATHIAS

Introduction

Syncope is a condition in which there is transient loss of consciousness due to reduction in cerebral blood flow. The term syncope is often used synony- mously with fainting, blackouts, passing out, and swooning. It is a common condition with both neurological (autonomic and non-autonomic) and car- diac causes. Psychologic and psychiatric conditions resulting in pseudosyn- cope are difficult to separate from true syncope [1].

There is increasing recognition that disturbances of the autonomic ner- vous system account for a large proportion of syncope cases. This was emphasised in a study of 641 patients with recurrent syncope and presyn- cope, in whom major neurological (non-autonomic) and cardiac causes had been previously excluded [2]. Following autonomic and allied investigations, half of the patients had an autonomic cause (Fig. 1). This highlighted the role that the autonomic nervous system plays–in part through the baroreceptor reflex, with efferents to the heart and sympathetic efferents to blood vessels in the heart – in the maintenance of blood pressure and thus in the causation of syncope.

This review provides a classification of disturbances of the autonomic nervous system that result in syncope. An outline of treatment options fol- lows.

Neurovascular Medicine Unit, Faculty of Medicine; Imperial College London at St

Mary’s Hospital, Autonomic Unit, National Hospital for Neurology & Neurosurgery,

Queen Square; Institute of Neurology, University College London, London, United

Kingdom

(2)

Diagnosis and Evaluation

Autonomic disturbances resulting in syncope may be intermittent (neurally mediated syncope and the postural tachycardia syndrome) (Table 1), due to drugs (Table 2), or the result of damage to the autonomic nervous system as a result of primary or secondary autonomic failure [3, 4] (Table 3). Diagnosis is dependent on a precise history, detailed clinical examination, and appro- priate tests [5, 6] (Table 4).

Fig. 1. Flow diagram showing investigations and diagnosis in 641 patients with recurrent syncope and presyncope. (Adapted from [2])

Table 1. Intermittent disturbances of the autonomic nervous system that cause syncope Neurally mediated syncope

Vasovagal syncope

Carotid sinus hypersensitivity

Miscellaneous causes (situational syncope)

Postural tachycardia syndrome (PoTS)

(3)

Table 2. Mechanisms by which drugs, chemicals, poisons, and toxins may cause syncope.

(adapted from [3])

By decreasing sympathetic activity Centrally acting

Clonidine, reserpine, anaesthetics Peripherally acting via

Sympathetic nerve endings (guanethidine, bethanidine) α-Adrenoceptor blockade (phenoxybenzamine) β-Adrenoceptor blockade (propranolol) By increasing cardiac parasympathetic activity

Organophosphates

Ciguatera (reef fish) poisoning By vasodilatation

Jellyfish and marine animal venoms By a first-dose effect

Prazosin, Captopril

By causing an autonomic neuropathy Alcohol, thiamine (vitamin B

1

) deficiency Vincristine, perhexiline maleate

Table 3. Disorders of the autonomic nervous system that cause syncope (adapted from [4]).

Primary autonomic failure Acute/subacute dysautonomias

Pure pandysautonomia

Pandysautonomia with neurological features Chronic autonomic failure syndromes

Pure autonomic failure

Multiple system atrophy (Shy-Drager syndrome) Autonomic failure with Parkinson’s disease Secondary autonomic failure

Congenital

Nerve growth factor deficiency Hereditary

Autosomal dominant trait Familial amyloid neuropathy

continue

(4)

Autosomal recessive trait

Familial dysautonomia, Riley-Day syndrome Dopamine beta-hydroxylase deficiency Metabolic

Diabetes mellitus Chronic renal failure Chronic liver disease Alcohol-induced Inflammatory

Guillain-Barre syndrome Transverse myelitis Infections

Bacterial: Tetanus

Viral: Human immunodeficiency virus infection Neoplasia

Brain tumours, especially of the third ventricle or posterior fossa Paraneoplastic, including adenocarcinomas of lung and pancreas Trauma

Cervical and high thoracic spinal-cord transection Table 3. continue

Table 4. Outline of investigations used in the evaluation of syncope due to disturbances of the autonomic nervous system (adapted from [6])

Head-up tilt (60°)

a

; standing

a

; Valsalva manoeuvre

a

Pressor stimuli

a

(isometric exercise, cold pressor, mental arithmetic)

Heart rate responses to: deep breathing

a

, hyperventilation

a

, standing

a

, head-up tilt

a

Liquid meal challenge

Modified exercise testing Carotid sinus massage

a

Indicates screening autonomic tests used in our London Units

Additional autonomic and allied tests, as described in [6], may need to be performed if

relevant to diagnosis and management

(5)

Treatment of Syncope Caused by Autonomic Nervous System Disturbances

The key components of treatment revolve around non-pharmacological mea- sures, drug treatment when appropriate, and the introduction of interven- tions such as cardiac pacemaker when relevant.

Neurally Mediated Syncope

This depends upon the cause, the most common being vasovagal syncope (Fig. 2). Reducing or preventing exposure to precipitating causes is of impor- tance, along with educating the patient about the disorder. A combination of non-pharmacological approaches, especially if supine blood pressure is low, should include a high-salt diet; fluid repletion; exercise to strengthen lower limb muscles; measures that activate the sympathetic nervous system, such as sustained hand grip, the use of the calf muscle pump to prevent pooling;

and various manoeuvres such as leg crossing [8–11]. Patients who have symptoms suggestive of an oncoming attack should sit and ideally lie head down, if needed with the legs upright. Pharmacological measures are used when non-pharmacological measures alone are not successful, especially if the supine blood pressure is low. These include low-dose fludrocortisone and

Fig. 2.Blood pressure and heart rate with continuous recordings from the Portapres II in

a patient with the mixed (cardio-inhibitory and vasodepressor) form of vasovagal syn-

cope. (Adapted from [7])

(6)

the sympathomimetics ephedrine and midodrine. 5-Hydroxytryptamine uptake release inhibitors have been used with varying success. In the cardio- inhibitory form of vasovagal syncope, a cardiac demand pacemaker is of value [12]. In some patients, especially those with phobias, cognitive behav- ioural psychotherapy is recommended.

In carotid sinus hypersensitivity, which is diagnosed more often in older patients, a cardiac pacemaker often is of benefit, both in the cardio-inhibito- ry and in the mixed forms (Fig. 3). In the vasodepressor form, non-pharma- cological and drug treatment as outlined above for vasovagal syncope often is needed. In unilateral hypersensitivity, denervation of the carotid sinus nerves has been employed.

In the miscellaneous (situational) group of syncope cases, treatment is tailored to the provoking cause. Thus, in patients with high spinal cord lesions on an artificial respirator, vagal activity is not opposed by sympathet- ic activity and tracheal stimulation can cause bradycardia and syncope; ade- quate oxygenation, atropine and, in some patients, a temporary cardiac demand pacemaker is indicated [14, 15]. In micturition-induced syncope, avoidance of precipitating factors, such as alcohol, and advice to empty the urinary bladder while sitting rather than standing may be all that is required.

Fig. 3. Continuous blood pressure and heart rate measured non-invasively (by Portapres

II) in a subject with falls of unknown cause. Left carotid sinus massage caused a fall in

both heart rate and blood pressure. The findings indicate the mixed (cardioinhibitory

and vasodepressor) form of carotid sinus hypersensitivity. (Adapted from [13])

(7)

Postural Tachycardia Syndrome

In this condition (Fig. 4), non-pharmacological measures are of particular importance and include avoiding hypovolaemia and contributory factors such as hyperventilation. Drugs such as fludrocortisone and midodrine are of value in some patients. Beta-adrenergic blockers, especially those that are cardioselective, reduce tachycardia. Specific approaches may be needed depending upon the cause and association; thus, in the joint hypermobility syndrome, the underlying collagen disorder (Ehlers-Danlos type III) needs to be addressed.

Drug-Induced Syncope

The pharmacological effect of drugs, their interactions with other agents, and modification of their actions in certain disease states, need to be borne in mind when syncope results from drugs. The ideal is withdrawal of drugs, but this may not always be possible, as in the treatment of parkinsonian syn- dromes (Table 5). Drugs such as alcohol and perhexiline maleate cause an autonomic neuropathy, and withdrawal alone may not result in recovery.

Fig. 4. Blood pressure and heart rate measured continuously before, during, and after 60°

head-up tilt by Portapres II in a normal subject (uppermost panel) and in a subject with

postural tachycardia syndrome (PoTS) (lowermost panel). (Adapted from [16]). The

middle panel is from a subject with orthostatic hypotension due to autonomic failure

(8)

Primary and Secondary Autonomic Failure

These conditions usually require a combination of approaches. The original disorder needs to be addressed, and orthostatic hypotension (Fig. 4 middle panel), which is the usual cause of syncope, must be treated. A combination of approaches often is needed (Table 6). Drugs used for the treatment of ortho- static hypotension act in different ways and frequently can be combined in lower dosages to provide benefit while reducing side effects (Table 7).

Table 5. The causative or contributory causes of syncope in a patient with parkinsonism (adapted from [5])

Side effects of anti-parkinsonian therapy:

L

-DOPA, bromocriptine, pergolide

Combination of

L

-DOPA and COMT inhibitors (tolcapone) MAO ‘b’ inhibitor, selegiline

Coincidental disease causing autonomic dysfunction Diabetes mellitus

Coincidental administration of drugs for an associated condition Antihypertensives

α-Adrenoceptor blockers (for benign prostatic hypertrophy) Vasodilators (for ischaemic heart disease)

Diuretics (for cardiac failure) Sildenafil (for erectile failure) Autonomic failure

Multiple system atrophy (Shy-Drager syndrome) Parkinson’s disease with autonomic failure Diffuse Lewy body disease

Table 6. Non-pharmacological and major pharmacological measures used in the man- agement of neurogenic orthostatic hypotension (adapted from [17])

Non-pharmacological measures To be avoided

Sudden head-up postural change (especially on waking) Prolonged recumbency

Straining during micturition and defaecation

High environmental temperature (including hot baths)

‘Severe’ exertion

Large meals (especially with refined carbohydrate) Alcohol

Drugs with vasodepressor properties

continue

(9)

To be introduced

Head-up tilt during sleep Small frequent meals High salt intake

Judicious exercise (including swimming) Body positions and manoeuvres To be considered

Elastic stockings Abdominal binders Water ingestion Pharmacological measures Starter drug: Fludrocortisone

Sympathomimetics: Ephedrine, midodrine

Specific targeting: Octreotide, desmopressin, erythropoietin Table 6. continue

Table 7. Outline of the major actions by which a variety of drugs may reduce orthostatic hypotension (adapted from [17])

Reducing salt loss/plasma volume expansion Mineralocorticoids (fludrocortisone) Reducing nocturnal polyuria V

2

-receptor agonists (desmopressin) Vasoconstriction: sympathetic

On resistance vessels (ephedrine, midodrine, phenylephrine, noradrenaline, clonidine, tyramine with monoamine oxidase inhibitors, yohimbine,

L

-dihydroxyphenylserine) On capacitance vessels (dihydroergotamine)

Vasoconstriction: non-sympathomimetic V

1

receptor agents – terlipressin

Ganglionic nicotinic-receptor stimulation Anticholinesterase inhibitors: pyridostigmine Preventing vasodilatation

Prostaglandin synthetase inhibitors (indomethacin, flurbiprofen) Dopamine receptor blockade (metaclopramide, domperidone) Beta

2

-adrenoceptor blockade (propranolol)

continue

(10)

References

1. Mathias CJ, Deguchi K, Bleasdale-Barr K, Smith S (2000) Familial vasovagal synco- pe and pseudosyncope: observations in a case with both natural and adopted siblings. Clin Auton Res 10:43–45

2. Mathias CJ, Deguchi K, Schatz I (2001) Observations on recurrent syncope and pre- syncope in 641 patients. Lancet 357:348–353

3. Mathias CJ (2004) Role of autonomic evaluation in the diagnosis and management of syncope. Clin Auton Res14(Suppl 1):45–54

4. Mathias CJ (2004) Disorders of the autonomic nervous system. In: Bradley WG, Daroff RB, Fenichel GM, Jancovich J (eds) Neurology in clinical practice, 3rd edn.

Butterworth-Heinemann, Boston, pp 2403–2240

5. Mathias CJ (2003)Autonomic diseases: clinical features and laboratory evaluation. J Neurol Neurosurg Psychiatry 74:iii31-iii41

6. Mathias CJ, Bannister R (2002) Investigation of autonomic disorders.In: Mathias CJ, Bannister R (eds) Autonomic failure: a textbook of clinical disorders of the autonomic nervous system, 4th edn. Oxford University Press, Oxford, pp169–195 7. Mathias CJ (2005) Orthostatic hypotension and orthostatic intolerance. In:

Jameson JL, DeGroot LJ (eds) Endocrinology, 5th edn. Elsevier, Philadelphia (in press)

8. van Dijk N, Harms MP, Linzer M, Wieling W (2000) Treatment of vasovagal synco- pe: pacemaker or crossing legs? Clin Autonom Res 10:347–349

9. Cooper VL, Hainsworth R (2002) Effects of dietary salt on orthostatic tolerance, blood pressure and baroreceptor sensitivity in patients with syncope. Clin Auton Res 12:234–241

10. Brignole M, Croci F, Menozzi C et al (2004) Isometric arm contraction at the onset of prodromal symptoms: a new first-line treatment for vasovagal syncope.In: A Raviele (ed) Cardiac arrhythmias 2004. Springer, Milan, pp 641–650

11. Mathias CJ, Young TM (2004) Water drinking in the management of orthostatic intolerance due to orthostatic hypotension, vasovagal syncope and the postural tachycardia syndrome. Eur J Neurol 11:613–619

12. Benditt DG (1999) Cardiac pacing for prevention of vasovagal syncope. J Am Coll Cardiol 33:21–23

Preventing postprandial hypotension Adrenosine receptor blockade (caffeine)

Peptide release inhibitors (somatostatin analogue: octreotide)

Increasing cardiac output

Beta-blockers with intrinsic sympathomimetic activity (pindolol, xamoterol) Dopamine agonists (ibopamine)

Increasing red cell mass

Erythropoietin

Table 7. continue

(11)

13. Mathias CJ (2005) Autonomic dysfunction and hypotension. In: Willerson JT, Cohn JN, WellensHJJ, Holmes DR Jr (eds) Cardiovascular medicine, 3rd edn. Elsevier, Philadelphia (in press)

14. Frankel HL, Mathias CJ, Spalding JM (1975) Mechanisms of reflex cardiac arrest in tetraplegic patients. Lancet 13:1183–1185

15. Mathias CJ (1976) Bradycardia and cardiac arrest during tracheal suction - mecha- nisms in tetraplegic patients. Eur J Intensive Care Med 2:147–156

16. Mathias CJ (2002) To stand on ones’ own legs. Clin Med 2:237–245

17. Mathias CJ (2003) Autonomic diseases – management. J Neurol Neurosurg

Psychiatry 74:42–47

Riferimenti

Documenti correlati

A RF model applied to triage data (vital signs, chief complaint, and active medical history) demonstrated equivalent or improved identification of clinical patient outcomes (need

The present paper is structured as follows: in Section 2 we list a few preliminary results; Section 3 is devoted to the analysis of the variational case, and to the proof of

After discussing the relevance of big data in relation to urban mobility policy (section 2), the paper examines the available big data and their possible uses in each step of the

To bridge the effect of the strain rate and the defects, a numerical model was built in the present work with zero- thickness cohesive elements based on the experimental results

Performance evaluation and comparison based on the Symbol error rate of thc conventional one-state and two-states RAKE receivers have been reported. The use of the

These tests include Valsalva maneuver testing, RR interval testing, tilt-table testing, microneurography, and the thermoregulatory sweat test1. This chapter reviews the

Patients with syncope associated with car- diac arrhythmias or who are thought to be at increased risk of sudden cardiac death (e.g., severe under- lying structural heart disease)

In the elderly patients in whom a cause of syncope is not established by the initial history and physical examination, further evaluation should focus on the following issues: (1)